Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 66 | 2023 | 1721 | 10.230 |
Why?
|
Radiotherapy, Intensity-Modulated | 21 | 2020 | 173 | 3.830 |
Why?
|
Androgen Antagonists | 18 | 2022 | 144 | 3.340 |
Why?
|
Radiation Injuries | 9 | 2019 | 155 | 3.320 |
Why?
|
Prostatectomy | 24 | 2022 | 471 | 2.980 |
Why?
|
Adenocarcinoma | 17 | 2019 | 1169 | 2.850 |
Why?
|
Prostate-Specific Antigen | 24 | 2022 | 353 | 2.790 |
Why?
|
Chemoradiotherapy | 7 | 2021 | 301 | 2.730 |
Why?
|
Radiotherapy Dosage | 28 | 2023 | 468 | 2.590 |
Why?
|
Neoplasm Recurrence, Local | 19 | 2022 | 1313 | 2.250 |
Why?
|
Anus Neoplasms | 4 | 2021 | 30 | 2.080 |
Why?
|
Radiotherapy, Conformal | 7 | 2016 | 83 | 1.980 |
Why?
|
Salvage Therapy | 16 | 2022 | 233 | 1.940 |
Why?
|
Urinary Incontinence | 4 | 2016 | 206 | 1.680 |
Why?
|
Radiotherapy, Adjuvant | 11 | 2018 | 292 | 1.670 |
Why?
|
Anticoagulants | 5 | 2022 | 408 | 1.660 |
Why?
|
Quality of Life | 7 | 2022 | 1585 | 1.630 |
Why?
|
Aged | 61 | 2024 | 18415 | 1.610 |
Why?
|
Male | 92 | 2023 | 40973 | 1.580 |
Why?
|
Aged, 80 and over | 34 | 2020 | 6509 | 1.500 |
Why?
|
Middle Aged | 64 | 2020 | 25028 | 1.470 |
Why?
|
Urinary Bladder Neoplasms | 5 | 2024 | 383 | 1.380 |
Why?
|
Prostate | 7 | 2023 | 378 | 1.320 |
Why?
|
Radiotherapy, Image-Guided | 5 | 2020 | 56 | 1.310 |
Why?
|
Humans | 110 | 2024 | 86653 | 1.240 |
Why?
|
Brachytherapy | 8 | 2019 | 119 | 1.230 |
Why?
|
Head and Neck Neoplasms | 6 | 2021 | 1052 | 1.210 |
Why?
|
Antineoplastic Agents, Hormonal | 4 | 2021 | 150 | 1.200 |
Why?
|
Neoplasm Staging | 22 | 2020 | 1939 | 1.180 |
Why?
|
Papillomavirus Infections | 2 | 2021 | 239 | 1.160 |
Why?
|
Follow-Up Studies | 20 | 2022 | 3640 | 1.090 |
Why?
|
Radiotherapy | 9 | 2019 | 328 | 1.070 |
Why?
|
Urogenital System | 4 | 2014 | 9 | 1.060 |
Why?
|
Fluorouracil | 7 | 2017 | 556 | 1.060 |
Why?
|
Radiosurgery | 4 | 2019 | 272 | 1.050 |
Why?
|
Capecitabine | 5 | 2024 | 96 | 1.030 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2022 | 134 | 0.970 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2022 | 384 | 0.960 |
Why?
|
Rectal Neoplasms | 4 | 2016 | 116 | 0.920 |
Why?
|
Liver Neoplasms | 3 | 2022 | 736 | 0.920 |
Why?
|
Rectal Diseases | 3 | 2013 | 24 | 0.910 |
Why?
|
Combined Modality Therapy | 20 | 2024 | 1686 | 0.880 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2018 | 236 | 0.880 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2018 | 2438 | 0.860 |
Why?
|
Cooperative Behavior | 1 | 2023 | 174 | 0.860 |
Why?
|
Pancreatic Neoplasms | 4 | 2017 | 645 | 0.820 |
Why?
|
Aspirin | 2 | 2013 | 156 | 0.810 |
Why?
|
Radiation Oncology | 4 | 2021 | 119 | 0.810 |
Why?
|
Treatment Outcome | 24 | 2020 | 7993 | 0.800 |
Why?
|
Gastrointestinal Tract | 3 | 2013 | 191 | 0.800 |
Why?
|
Patient Care Team | 1 | 2023 | 280 | 0.790 |
Why?
|
Risk Assessment | 12 | 2020 | 2262 | 0.770 |
Why?
|
Urinary Bladder | 3 | 2024 | 246 | 0.760 |
Why?
|
Chemoradiotherapy, Adjuvant | 3 | 2017 | 35 | 0.750 |
Why?
|
Hypersensitivity | 1 | 2022 | 154 | 0.740 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2018 | 1076 | 0.730 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2021 | 118 | 0.720 |
Why?
|
Magnetic Resonance Imaging | 3 | 2018 | 3362 | 0.700 |
Why?
|
Long Term Adverse Effects | 1 | 2019 | 6 | 0.700 |
Why?
|
Cystectomy | 3 | 2024 | 102 | 0.700 |
Why?
|
Retrospective Studies | 24 | 2021 | 8491 | 0.700 |
Why?
|
Fiducial Markers | 2 | 2020 | 7 | 0.700 |
Why?
|
Rectum | 4 | 2014 | 146 | 0.690 |
Why?
|
Analysis of Variance | 9 | 2015 | 912 | 0.680 |
Why?
|
Neoplasm Grading | 9 | 2022 | 357 | 0.670 |
Why?
|
Hematuria | 3 | 2022 | 49 | 0.670 |
Why?
|
Lymph Node Excision | 4 | 2017 | 217 | 0.670 |
Why?
|
Prognosis | 15 | 2020 | 3680 | 0.650 |
Why?
|
Adult | 32 | 2020 | 25649 | 0.630 |
Why?
|
Urologic Neoplasms | 1 | 2018 | 77 | 0.620 |
Why?
|
Tomography, X-Ray Computed | 6 | 2020 | 2601 | 0.620 |
Why?
|
Time Factors | 15 | 2020 | 5210 | 0.600 |
Why?
|
Organs at Risk | 3 | 2020 | 41 | 0.580 |
Why?
|
Leukopenia | 1 | 2016 | 65 | 0.580 |
Why?
|
Organ Transplantation | 1 | 2020 | 265 | 0.580 |
Why?
|
Pelvic Bones | 1 | 2016 | 44 | 0.560 |
Why?
|
Prospective Studies | 8 | 2022 | 4213 | 0.560 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2015 | 468 | 0.550 |
Why?
|
Risk Factors | 10 | 2020 | 5417 | 0.540 |
Why?
|
Thrombocytopenia | 1 | 2016 | 183 | 0.530 |
Why?
|
Biomarkers, Tumor | 3 | 2012 | 1464 | 0.530 |
Why?
|
Cohort Studies | 8 | 2022 | 2767 | 0.520 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 977 | 0.510 |
Why?
|
Bone Marrow | 1 | 2016 | 435 | 0.510 |
Why?
|
Sexuality | 1 | 2014 | 40 | 0.500 |
Why?
|
Tumor Burden | 5 | 2019 | 289 | 0.490 |
Why?
|
Multivariate Analysis | 8 | 2017 | 999 | 0.480 |
Why?
|
Survival Rate | 9 | 2019 | 1863 | 0.470 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2013 | 229 | 0.460 |
Why?
|
Urinary Retention | 2 | 2010 | 40 | 0.450 |
Why?
|
Transurethral Resection of Prostate | 2 | 2010 | 9 | 0.450 |
Why?
|
Antineoplastic Agents | 7 | 2019 | 2360 | 0.440 |
Why?
|
Hospitalization | 1 | 2018 | 849 | 0.440 |
Why?
|
CA-19-9 Antigen | 1 | 2012 | 11 | 0.440 |
Why?
|
SEER Program | 6 | 2020 | 190 | 0.440 |
Why?
|
Herpes Zoster | 1 | 2013 | 78 | 0.440 |
Why?
|
Postoperative Complications | 2 | 2020 | 2207 | 0.430 |
Why?
|
Neoadjuvant Therapy | 2 | 2012 | 318 | 0.430 |
Why?
|
Chemoprevention | 1 | 2012 | 91 | 0.420 |
Why?
|
Carcinoembryonic Antigen | 1 | 2012 | 41 | 0.420 |
Why?
|
Portal Vein | 1 | 2012 | 120 | 0.420 |
Why?
|
Kaplan-Meier Estimate | 8 | 2017 | 860 | 0.410 |
Why?
|
Lymphatic Metastasis | 5 | 2017 | 486 | 0.410 |
Why?
|
Diabetes Complications | 1 | 2013 | 207 | 0.400 |
Why?
|
Risk | 4 | 2020 | 674 | 0.400 |
Why?
|
Radioimmunodetection | 2 | 2008 | 13 | 0.400 |
Why?
|
Deoxycytidine | 2 | 2012 | 237 | 0.390 |
Why?
|
Female | 25 | 2022 | 44537 | 0.380 |
Why?
|
Prostatism | 1 | 2010 | 5 | 0.380 |
Why?
|
Lymph Nodes | 3 | 2020 | 533 | 0.380 |
Why?
|
Gastrointestinal Neoplasms | 3 | 2021 | 106 | 0.370 |
Why?
|
Urination Disorders | 1 | 2010 | 50 | 0.370 |
Why?
|
Body Burden | 1 | 2009 | 9 | 0.360 |
Why?
|
Withholding Treatment | 1 | 2010 | 112 | 0.360 |
Why?
|
Venous Thrombosis | 1 | 2012 | 243 | 0.350 |
Why?
|
Practice Guidelines as Topic | 1 | 2016 | 1036 | 0.350 |
Why?
|
Dose-Response Relationship, Radiation | 4 | 2016 | 188 | 0.340 |
Why?
|
Smoking | 1 | 2013 | 609 | 0.340 |
Why?
|
Survival Analysis | 9 | 2019 | 1538 | 0.340 |
Why?
|
Models, Statistical | 1 | 2012 | 575 | 0.330 |
Why?
|
Leucovorin | 3 | 2017 | 218 | 0.330 |
Why?
|
Comorbidity | 3 | 2021 | 943 | 0.320 |
Why?
|
Carcinoma, Renal Cell | 3 | 2019 | 426 | 0.310 |
Why?
|
Hemorrhage | 1 | 2009 | 268 | 0.300 |
Why?
|
Ganglioglioma | 1 | 2006 | 4 | 0.290 |
Why?
|
Disease Progression | 3 | 2020 | 1531 | 0.290 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 3 | 2020 | 176 | 0.290 |
Why?
|
Kidney Neoplasms | 3 | 2019 | 621 | 0.290 |
Why?
|
Treatment Failure | 4 | 2016 | 285 | 0.290 |
Why?
|
Testicular Neoplasms | 2 | 2019 | 105 | 0.280 |
Why?
|
Disease-Free Survival | 7 | 2014 | 1204 | 0.280 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 378 | 0.280 |
Why?
|
Abdomen | 1 | 2006 | 122 | 0.270 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2006 | 109 | 0.270 |
Why?
|
Postoperative Period | 3 | 2015 | 303 | 0.270 |
Why?
|
Carcinoma | 2 | 2012 | 436 | 0.270 |
Why?
|
United States | 7 | 2021 | 6674 | 0.270 |
Why?
|
Proportional Hazards Models | 5 | 2017 | 859 | 0.250 |
Why?
|
Probability | 3 | 2012 | 355 | 0.240 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2006 | 261 | 0.240 |
Why?
|
Urethral Neoplasms | 2 | 2018 | 10 | 0.240 |
Why?
|
Neoplasms, Second Primary | 1 | 2006 | 252 | 0.240 |
Why?
|
Motion | 1 | 2023 | 85 | 0.230 |
Why?
|
Neoplasm, Residual | 3 | 2012 | 162 | 0.230 |
Why?
|
Patient Selection | 3 | 2017 | 686 | 0.220 |
Why?
|
Propensity Score | 2 | 2020 | 136 | 0.220 |
Why?
|
Ipilimumab | 1 | 2022 | 58 | 0.220 |
Why?
|
Positron Emission Tomography Computed Tomography | 2 | 2020 | 86 | 0.220 |
Why?
|
Severity of Illness Index | 4 | 2013 | 1801 | 0.210 |
Why?
|
Contrast Media | 2 | 2016 | 1078 | 0.210 |
Why?
|
Incidence | 2 | 2022 | 1577 | 0.200 |
Why?
|
Radiation Oncologists | 2 | 2021 | 13 | 0.200 |
Why?
|
Ticlopidine | 2 | 2012 | 25 | 0.200 |
Why?
|
Neoplasm Metastasis | 3 | 2020 | 1056 | 0.190 |
Why?
|
Radium | 1 | 2020 | 7 | 0.190 |
Why?
|
Oncologists | 1 | 2021 | 36 | 0.190 |
Why?
|
Brain Neoplasms | 1 | 2006 | 763 | 0.190 |
Why?
|
Warfarin | 2 | 2012 | 103 | 0.180 |
Why?
|
Platelet Count | 1 | 2020 | 92 | 0.180 |
Why?
|
Internship and Residency | 2 | 2021 | 1004 | 0.180 |
Why?
|
Radiologic Health | 1 | 2019 | 2 | 0.180 |
Why?
|
Androgen Receptor Antagonists | 1 | 2019 | 18 | 0.180 |
Why?
|
Sezary Syndrome | 1 | 2019 | 8 | 0.170 |
Why?
|
Phenylthiohydantoin | 1 | 2019 | 41 | 0.170 |
Why?
|
Mycosis Fungoides | 1 | 2019 | 23 | 0.170 |
Why?
|
Depsipeptides | 1 | 2019 | 29 | 0.170 |
Why?
|
Electrons | 1 | 2019 | 49 | 0.170 |
Why?
|
Spinal Neoplasms | 1 | 2019 | 50 | 0.170 |
Why?
|
Thoracic Vertebrae | 1 | 2019 | 49 | 0.170 |
Why?
|
Feasibility Studies | 1 | 2021 | 751 | 0.170 |
Why?
|
Mitomycin | 2 | 2016 | 29 | 0.170 |
Why?
|
Colorectal Neoplasms | 1 | 2006 | 938 | 0.160 |
Why?
|
Transplantation Conditioning | 1 | 2020 | 373 | 0.160 |
Why?
|
Proctoscopy | 1 | 2017 | 1 | 0.160 |
Why?
|
Prostatic Diseases | 1 | 2017 | 3 | 0.160 |
Why?
|
Patient Reported Outcome Measures | 1 | 2019 | 166 | 0.160 |
Why?
|
Digital Rectal Examination | 1 | 2017 | 7 | 0.160 |
Why?
|
Neoplasms | 1 | 2013 | 2898 | 0.160 |
Why?
|
Surveys and Questionnaires | 4 | 2021 | 2501 | 0.150 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 111 | 0.150 |
Why?
|
Phantoms, Imaging | 1 | 2020 | 429 | 0.150 |
Why?
|
Movement | 1 | 2020 | 299 | 0.150 |
Why?
|
Clinical Competence | 3 | 2021 | 751 | 0.150 |
Why?
|
Organoplatinum Compounds | 1 | 2017 | 94 | 0.150 |
Why?
|
Immunotherapy | 1 | 2022 | 629 | 0.150 |
Why?
|
Postoperative Care | 1 | 2018 | 221 | 0.150 |
Why?
|
Medicare | 1 | 2020 | 410 | 0.150 |
Why?
|
Ilium | 1 | 2016 | 18 | 0.150 |
Why?
|
Remission Induction | 1 | 2018 | 722 | 0.150 |
Why?
|
Organ Sparing Treatments | 1 | 2016 | 38 | 0.150 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2018 | 164 | 0.140 |
Why?
|
Camptothecin | 1 | 2017 | 189 | 0.140 |
Why?
|
Nephrectomy | 1 | 2019 | 294 | 0.140 |
Why?
|
Transcriptome | 1 | 2021 | 580 | 0.140 |
Why?
|
Internationality | 1 | 2016 | 69 | 0.140 |
Why?
|
Sensitivity and Specificity | 3 | 2016 | 1991 | 0.140 |
Why?
|
Reproducibility of Results | 3 | 2017 | 2705 | 0.140 |
Why?
|
Urology | 1 | 2017 | 110 | 0.140 |
Why?
|
Patient Safety | 1 | 2018 | 212 | 0.140 |
Why?
|
Neutropenia | 1 | 2016 | 215 | 0.140 |
Why?
|
Software | 1 | 2020 | 654 | 0.130 |
Why?
|
Neoplasm Invasiveness | 3 | 2024 | 552 | 0.130 |
Why?
|
Seminoma | 1 | 2015 | 10 | 0.130 |
Why?
|
Orchiectomy | 1 | 2015 | 68 | 0.130 |
Why?
|
Quality Improvement | 1 | 2019 | 428 | 0.130 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2014 | 30 | 0.130 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2015 | 47 | 0.130 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 916 | 0.130 |
Why?
|
Carboplatin | 1 | 2015 | 286 | 0.120 |
Why?
|
Skin Neoplasms | 1 | 2019 | 546 | 0.120 |
Why?
|
Health Surveys | 1 | 2014 | 239 | 0.120 |
Why?
|
Education, Medical, Graduate | 1 | 2017 | 369 | 0.120 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2013 | 33 | 0.110 |
Why?
|
Radiography | 2 | 2006 | 813 | 0.110 |
Why?
|
Kidney | 1 | 2019 | 1242 | 0.110 |
Why?
|
Metalloporphyrins | 1 | 2012 | 26 | 0.110 |
Why?
|
Enoxaparin | 1 | 2012 | 23 | 0.110 |
Why?
|
Prevalence | 1 | 2016 | 1239 | 0.110 |
Why?
|
Lower Urinary Tract Symptoms | 1 | 2013 | 59 | 0.110 |
Why?
|
Constriction, Pathologic | 1 | 2013 | 213 | 0.110 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 469 | 0.100 |
Why?
|
Curriculum | 1 | 2016 | 539 | 0.100 |
Why?
|
Age Factors | 3 | 2010 | 1851 | 0.100 |
Why?
|
Regression Analysis | 2 | 2017 | 596 | 0.100 |
Why?
|
Longitudinal Studies | 1 | 2014 | 1019 | 0.100 |
Why?
|
Students, Medical | 1 | 2016 | 384 | 0.100 |
Why?
|
Proctitis | 1 | 2010 | 12 | 0.100 |
Why?
|
Genetic Vectors | 1 | 2012 | 439 | 0.100 |
Why?
|
Stomach Neoplasms | 1 | 2014 | 266 | 0.100 |
Why?
|
Algorithms | 2 | 2019 | 1830 | 0.100 |
Why?
|
Neck Dissection | 2 | 2008 | 65 | 0.100 |
Why?
|
Radiotherapy, High-Energy | 1 | 2010 | 49 | 0.090 |
Why?
|
Genetic Therapy | 1 | 2012 | 342 | 0.090 |
Why?
|
Seminal Vesicles | 2 | 2016 | 39 | 0.090 |
Why?
|
Breast Neoplasms | 1 | 2004 | 2903 | 0.090 |
Why?
|
Registries | 3 | 2010 | 703 | 0.090 |
Why?
|
Predictive Value of Tests | 2 | 2006 | 1673 | 0.090 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2010 | 103 | 0.090 |
Why?
|
Antiviral Agents | 1 | 2013 | 510 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2012 | 683 | 0.080 |
Why?
|
Urologic Diseases | 1 | 2009 | 45 | 0.080 |
Why?
|
Thymidine Phosphorylase | 1 | 2008 | 5 | 0.080 |
Why?
|
Young Adult | 3 | 2019 | 5977 | 0.080 |
Why?
|
Vitamin B Complex | 1 | 2008 | 21 | 0.080 |
Why?
|
Acute Disease | 1 | 2010 | 826 | 0.080 |
Why?
|
Indium Radioisotopes | 1 | 2007 | 10 | 0.080 |
Why?
|
Pharynx | 1 | 2006 | 45 | 0.070 |
Why?
|
Recurrence | 1 | 2009 | 1139 | 0.070 |
Why?
|
Iodine Radioisotopes | 1 | 2006 | 134 | 0.070 |
Why?
|
Cisplatin | 2 | 2024 | 612 | 0.070 |
Why?
|
Chicago | 1 | 2009 | 1379 | 0.060 |
Why?
|
Infusions, Intravenous | 1 | 2005 | 429 | 0.060 |
Why?
|
Palliative Care | 1 | 2006 | 257 | 0.060 |
Why?
|
Sampling Studies | 1 | 2004 | 70 | 0.060 |
Why?
|
Disease Management | 2 | 2017 | 327 | 0.060 |
Why?
|
Digestive System | 1 | 2003 | 42 | 0.060 |
Why?
|
Physics | 1 | 2021 | 22 | 0.050 |
Why?
|
Mastectomy | 1 | 2004 | 243 | 0.050 |
Why?
|
Androgens | 1 | 2021 | 167 | 0.050 |
Why?
|
Patient Care Planning | 1 | 2021 | 81 | 0.050 |
Why?
|
Perception | 1 | 2021 | 168 | 0.050 |
Why?
|
Child, Preschool | 1 | 2006 | 3613 | 0.040 |
Why?
|
Cell Cycle | 1 | 2021 | 502 | 0.040 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2021 | 294 | 0.040 |
Why?
|
Retreatment | 1 | 2019 | 107 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 159 | 0.040 |
Why?
|
Placebos | 1 | 2019 | 218 | 0.040 |
Why?
|
Nitriles | 1 | 2019 | 149 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2019 | 176 | 0.040 |
Why?
|
Inflammation | 1 | 2004 | 924 | 0.040 |
Why?
|
Benzamides | 1 | 2019 | 229 | 0.040 |
Why?
|
Aftercare | 1 | 2019 | 85 | 0.040 |
Why?
|
Kallikreins | 1 | 2017 | 47 | 0.040 |
Why?
|
Delphi Technique | 1 | 2017 | 80 | 0.040 |
Why?
|
Efficiency | 1 | 2017 | 40 | 0.040 |
Why?
|
Pelvis | 1 | 2017 | 95 | 0.040 |
Why?
|
Radiometry | 1 | 2016 | 53 | 0.040 |
Why?
|
Job Satisfaction | 1 | 2017 | 73 | 0.040 |
Why?
|
Equipment Design | 1 | 2017 | 406 | 0.040 |
Why?
|
Ultrasonography, Interventional | 1 | 2016 | 121 | 0.030 |
Why?
|
Texas | 1 | 2016 | 101 | 0.030 |
Why?
|
Insurance, Health | 1 | 2017 | 160 | 0.030 |
Why?
|
Sample Size | 1 | 2016 | 130 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 364 | 0.030 |
Why?
|
Odds Ratio | 1 | 2017 | 678 | 0.030 |
Why?
|
Child | 1 | 2006 | 6928 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 865 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2016 | 180 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2019 | 1823 | 0.030 |
Why?
|
Internet | 1 | 2017 | 312 | 0.030 |
Why?
|
Educational Measurement | 1 | 2016 | 225 | 0.030 |
Why?
|
Preoperative Period | 1 | 2014 | 91 | 0.030 |
Why?
|
Adolescent | 1 | 2006 | 8982 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2020 | 1204 | 0.030 |
Why?
|
Databases, Factual | 1 | 2016 | 814 | 0.030 |
Why?
|
Fatigue | 1 | 2013 | 174 | 0.030 |
Why?
|
Cell Differentiation | 2 | 2008 | 1458 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2014 | 394 | 0.020 |
Why?
|
Nomograms | 1 | 2007 | 28 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2007 | 227 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2008 | 1806 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2008 | 1169 | 0.010 |
Why?
|